Yesterday, the OMB’s Office of Information and Regulatory Affairs (OIRA) announced that it had approved a notice of proposed rulemaking from the EPA on “1-Bromopropane (1-BP); Regulation Under the Toxic Substances Control Act (TSCA)”. The NPRM was submitted to OIRA on December 12th, 2023.
According to the Spring 2024 Unified Agenda entry for this rulemaking:
“This proposed rulemaking will address the unreasonable risk of injury to health presented by 1-bromopropane (1-BP). Section 6(a) of the Toxic Substances Control Act (TSCA) requires EPA address by rule any unreasonable risk identified in a TSCA risk evaluation and apply requirements to the extent necessary so the chemical no longer presents unreasonable risk. The Agency’s development of this rule incorporates significant stakeholder outreach and public participation, including over 40 external meetings as well as required Federalism, Tribal, and Environmental Justice consultations and a Small Businesses Advocacy Review Panel. Specifically, EPA engaged in discussions with industry, non-governmental organizations, other government agencies, technical experts and users of 1-BP, and the general public to hear from users, academics, manufacturers, and members of the public health community about practices related to commercial uses of 1-BP. EPA's risk evaluation for 1-BP, describing the conditions of use, is in docket EPA-HQ-OPPT-2019-0235 [link added], with the 2022 unreasonable risk determination and additional materials in docket EPA-HQ-OPPT-2016-0741 [link added].”
Additional information is available on the EPA’s Risk Evaluation for 1-Bromopropane (1-BP) web site.
As with most TSCA risk reduction rules, I will probably not
cover this rulemaking in any detail. I will, however, at least mention it’s
publication in the appropriate Short Takes post.
Posts
No comments:
Post a Comment